| |
Total (n = 125)
|
Survivors (n = 97)
|
Non-survivors (n = 28)
|
P
|
|---|
|
Covid severity*
| | | |
0.001
|
|
Mild
|
37.6% (47)
|
48.5% (47)
|
0.0% (0)
| |
|
Moderate
|
27.2% (34)
|
35.0% (34)
|
0.0% (0)
| |
|
Severe
|
35.2% (44)
|
16.5% (16)
|
100% (28)
| |
|
Treatment
|
|
Oxygen therapy
|
60.0% (75)
|
50.5% (49)
|
92.9% (26)
|
< 0.0001
|
|
Maximal flow (L/min)
|
3.0 (2.0–6.0)
|
3.0 (2.0–6.0)
|
5.0 (2.5–15.0)
|
0.018
|
|
Antibiotics use
|
61.6% (77)
|
57.7% (56)
|
75.0% (21)
|
0.074
|
|
Combination of antibiotics
|
33.6% (42)
|
29.9% (29)
|
46.4% (13)
|
0.082
|
|
Beta-lactamine
|
54.4% (68)
|
50.5% (49)
|
67.9% (19)
|
0.079
|
|
Macrolides
|
37.6% (47)
|
35.1% (34)
|
46.4% (13)
|
0.279
|
|
2nd line antibiotics
|
17.6% (22)
|
14.4% (14)
|
28.6% (8)
|
0.096
|
|
Steroids
|
8.0% (10)
|
8.2% (8)
|
7.1% (2)
|
1.000
|
|
Hydroxychloroquine
|
16.8% (21)
|
16.5% (16)
|
17.9% (5)
|
1.000
|
|
Neuroleptics
|
4.8% (6)
|
5.2% (5)
|
3.6% (1)
|
0.678
|
|
Complications
|
|
ARDS
|
25.6% (32)
|
6.2% (6)
|
92.9% (26)
|
< 0.0001
|
|
Cardiac injury
|
13.6% (17)
|
9.3% (9)
|
28.6% (8)
|
0.024
|
|
ACKI
|
16.8% (21)
|
12.4% (12)
|
32.1% (9)
|
0.021
|
|
Bacterial superinfection
|
14.4% (18)
|
11.3% (11)
|
25.0% (7)
|
0.122
|
|
Behavioural disorder
|
19.2% (24)
|
21.6% (21)
|
10.7% (3)
|
0.278
|
|
Diabetic ketoacidosis
|
2.4% (3)
|
3.1% (3)
|
0.0% (0)
|
1.000
|
|
Seizure
|
2.4% (3)
|
2.1% (2)
|
3.6% (1)
|
0.536
|
|
Stroke
|
2.4% (3)
|
2.1% (2)
|
3.6% (1)
|
1.000
|
|
Outcome
|
Total (n=125)
|
Survivors (n=97)
|
Non-survivors (n=28)
| |
|
Total mortality
|
22.4% (28)
| | | |
|
Delay admission-death
| | |
8.5 (3.7–16)
|
|
Length of stay
| |
16 (11–19.7)
| | |
|
Discharge home before end of follow-up
|
40.2% (39)
| | |
- Data are median (IQI), % (n). P values > 0.05 (bold) indicates significant differences between survivors and non-survivors
- *COVID severity defined according to WHO guidelines
- ACKI acute kidney injury, ARDS acute respiratory distress syndrome
